Trial Profile
A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects with Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Cetrelimab (Primary) ; Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 18 Dec 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 16 Dec 2021 This trial has been completed in France , according to European Clinical Trials Database record.
- 07 Jan 2021 Planned End Date changed from 15 Dec 2020 to 30 Nov 2021.